Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook

Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal to the U.S. Court of Appeals for the Federal Circuit to reverse the District Court’s rulingNo generic Entresto product has received FDA approval as of todayPending a final appeal decision and other ongoing litigation involving multiple patents, any launch once generics receive FDA approval would be ‘at risk

Related Keywords

Switzerland ,United States ,Delaware ,West Virginia ,America ,Sloan Simpson ,Nicole Zinsli Somm ,Marlena Abdinoor ,Satoshi Sugimoto ,Julie Masow ,Samir Shah ,Isabella Zinck ,Parag Mahanti ,Michael Meo ,Richard Jarvis ,Us Court ,Novartis Group ,Twitter ,Exchange Commission ,District Court ,Us District Court ,Group Sales ,Group Core Opinc ,Novartis ,Mylan Pharmaceuticals Inc ,Federal Circuit ,Core Opinc ,Orange Book ,Abbreviated New Drug Application ,Orange Book Listed ,Northern District ,Mylan Pharmaceuticals ,Entresto ,District Of Delaware ,Pediatric Exclusivity ,Potential ,